Poherdy (pertuzumab-dpzb, biosimilar to Perjeta)
Named-patient access overview. Poherdy is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Poherdy
Poherdy (pertuzumab-dpzb) is a biosimilar to pertuzumab, the reference humanized IgG1 monoclonal antibody marketed by Genentech and Roche as Perjeta. Pertuzumab binds the HER2 receptor at its dimerization domain (subdomain II) and blocks HER2 from pairing with HER3, HER4, and EGFR. This complements trastuzumab, which binds a different HER2 epitope, and the combination produces a more complete blockade of HER2 signaling in HER2-positive breast cancer.
Poherdy is administered by intravenous infusion and is typically given in combination with trastuzumab plus a taxane chemotherapy backbone. Reference-product indications for pertuzumab include neoadjuvant, adjuvant, and metastatic HER2-positive breast cancer settings. Biosimilar-specific indication coverage and any carve-outs should be confirmed against the current FDA label for pertuzumab-dpzb before prescribing.
For international patients, Poherdy is sourced by Reserve Meds from a DSCSA-compliant US specialty wholesaler with full serial traceability and may be accessible via Named Patient Program or personal-import pathways depending on destination country.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Poherdy
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Poherdy for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Poherdy is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Poherdy in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Poherdy
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.